Nemaura Medical Analyst Ratings
Nemaura Medical Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/21/2023 | 220.47% | HC Wainwright & Co. | $7 → $2.5 | Maintains | Buy |
| 07/17/2023 | 412.75% | EF Hutton | $6 → $4 | Maintains | Buy |
| 03/30/2023 | 669.13% | EF Hutton | → $6 | Reiterates | → Buy |
| 02/28/2023 | 669.13% | EF Hutton | → $6 | Maintains | Buy |
| 02/27/2023 | 797.32% | HC Wainwright & Co. | $8 → $7 | Maintains | Buy |
| 08/19/2022 | 925.51% | HC Wainwright & Co. | $12 → $8 | Maintains | Buy |
| 03/29/2022 | 1438.26% | HC Wainwright & Co. | → $12 | Initiates Coverage On | → Buy |
| 12/02/2021 | 861.42% | EF Hutton | → $7.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月21日 | 220.47% | HC Wainwright公司 | $7→$2.5 | 維護 | 買 |
| 07/17/2023 | 412.75% | EF Hutton | $6→$4 | 維護 | 買 |
| 03/30/2023 | 669.13% | EF Hutton | →$6 | 重申 | →購買 |
| 02/28/2023 | 669.13% | EF Hutton | →$6 | 維護 | 買 |
| 02/27/2023 | 797.32% | HC Wainwright公司 | $8→$7 | 維護 | 買 |
| 2022年08月19日 | 925.51% | HC Wainwright公司 | $12→$8 | 維護 | 買 |
| 03/29/2022 | 1438.26% | HC Wainwright公司 | →$12 | 開始承保 | →購買 |
| 12/02/2021 | 861.42% | EF Hutton | →$7.5 | 開始承保 | →購買 |
What is the target price for Nemaura Medical (NMRD)?
Nemaura Medical(NMRD)的目標價是多少？
The latest price target for Nemaura Medical (NASDAQ: NMRD) was reported by HC Wainwright & Co. on August 21, 2023. The analyst firm set a price target for $2.50 expecting NMRD to rise to within 12 months (a possible 220.47% upside). 5 analyst firms have reported ratings in the last year.
納斯達克(Nemaura Medical)(納斯達克代碼：NMRD)的最新目標價是由HC Wainwright&Co.於2023年8月21日報道的。這家分析公司將目標價定為2.5美元，預計NMRD將在12個月內升至(可能上漲220.47%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Nemaura Medical (NMRD)?
分析師最近對Nemaura Medical(NMRD)的評級是多少？
The latest analyst rating for Nemaura Medical (NASDAQ: NMRD) was provided by HC Wainwright & Co., and Nemaura Medical maintained their buy rating.
分析師對Nemaura Medical(納斯達克代碼：NMRD)的最新評級由HC Wainwright&Co.提供，Nemaura Medical維持買入評級。
When is the next analyst rating going to be posted or updated for Nemaura Medical (NMRD)?
Nemaura Medical(NMRD)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Nemaura Medical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Nemaura Medical was filed on August 21, 2023 so you should expect the next rating to be made available sometime around August 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Nemaura Medical的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Nemaura Medical的上一次評級是在2023年8月21日提交的，因此您應該預計下一次評級將在2024年8月21日左右提供。
Is the Analyst Rating Nemaura Medical (NMRD) correct?
分析師對Nemaura Medical(NMRD)的評級正確嗎？
While ratings are subjective and will change, the latest Nemaura Medical (NMRD) rating was a maintained with a price target of $7.00 to $2.50. The current price Nemaura Medical (NMRD) is trading at is $0.78, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Nemaura Medical(NMRD)評級維持不變，目標價在7.00美元至2.50美元之間。Nemaura Medical(NMRD)目前的交易價格為0.78美元，超出了分析師的預測區間。